Therapeutic potential of mesenchymal stem/stromal cells therapy

Recently, mesenchymal stem/stromal cells (MSCs) therapy has become an emerging therapeutic modality for the treatment of inflammatory bowel disease (IBD), given their immunoregulatory and pro-survival attributes. MSCs alleviate dysregulated inflammatory responses through the secretion of a myriad of...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of medical research Vol. 28; no. 1
Main Authors Saadh, Mohamed J, Mikhailova, Maria V, Rasoolzadegan, Soheil, Falaki, Mojgan, Akhavanfar, Roozbeh, Gonzáles, José Luis Arias, Rigi, Amir, Kiasari, Bahman Abedi
Format Journal Article
LanguageEnglish
Published BioMed Central Ltd 27.01.2023
Subjects
B cells
Bone morphogenetic proteins
Care and treatment
Development and progression
Gastrointestinal diseases
Health aspects
Inflammation
Interleukins
Medical research
Medicine, Experimental
Microbiota (Symbiotic organisms)
Prostaglandins E
Stem cells
Transforming growth factors
Tumor necrosis factor
Honduras
Online AccessGet full text

Cover

More Information
Summary:Recently, mesenchymal stem/stromal cells (MSCs) therapy has become an emerging therapeutic modality for the treatment of inflammatory bowel disease (IBD), given their immunoregulatory and pro-survival attributes. MSCs alleviate dysregulated inflammatory responses through the secretion of a myriad of anti-inflammatory mediators, such as interleukin 10 (IL-10), transforming growth factor-[beta] (TGF[beta]), prostaglandin E2 (PGE2), tumor necrosis factor-stimulated gene-6 (TSG-6), etc. Indeed, MSC treatment of IBD is largely carried out through local microcirculation construction, colonization and repair, and immunomodulation, thus alleviating diseases severity. The clinical therapeutic efficacy relies on to the marked secretion of various secretory molecules from viable MSCs via paracrine mechanisms that are required for gut immuno-microbiota regulation and the proliferation and differentiation of surrounding cells like intestinal epithelial cells (IECs) and intestinal stem cells (ISCs). For example, MSCs can induce IECs proliferation and upregulate the expression of tight junction (TJs)-associated protein, ensuring intestinal barrier integrity. Concerning the encouraging results derived from animal studies, various clinical trials are conducted or ongoing to address the safety and efficacy of MSCs administration in IBD patients. Although the safety and short-term efficacy of MSCs administration have been evinced, the long-term efficacy of MSCs transplantation has not yet been verified. Herein, we have emphasized the illumination of the therapeutic capacity of MSCs therapy, including naïve MSCs, preconditioned MSCs, and also MSCs-derived exosomes, to alleviate IBD severity in experimental models. Also, a brief overview of published clinical trials in IBD patients has been delivered. Keywords: Mesenchymal stem/stromal cells (MSCs), Inflammatory bowel disease (IBD), Inflammation, Intestinal integrity, Cytokines
ISSN:0949-2321
2047-783X
DOI:10.1186/s40001-023-01008-7